FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its ...
The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...
Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...
Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results